Morepen Laboratories Limited Share Price & Analysis

Morepen Labs announces Q2 and H1 FY27 results

*Morepen Labs announces Q2 and H1 FY27 results* released via newspaper publication. Financial performance for the quarter and half year ended 30 September 2026 is now public. **Key numbers** include revenue and profit figures impacting near-term outlook. Special window for physical share dematerialization also announced. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen Q2 revenue hits record ₹755 Cr, EBITDA up 273%

*Morepen Q2 revenue hits record ₹755 Cr, EBITDA up 273%* — Morepen Laboratories reported a record Q2 revenue of **₹755 Cr**, with EBITDA soaring **273%** to **₹132 Cr**, driven by strong CDMO momentum. H1 EBITDA reached **₹220 Cr**, signaling a major leap in profitability and operational scale. This sharp earnings scale-up reflects robust demand and execution efficiency. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen Labs reports Q2FY26 financial results

*Morepen Labs reports Q2FY26 financial results.* The company released its unaudited financial results for the quarter ended September 30, 2026. Results were in line with market expectations, with revenue at **₹320 crore** and net profit at **₹38 crore**. No major corporate actions were announced. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings

Morepen Labs reports Q1 FY26 financial results

*Morepen Labs reports Q1 FY26 financial results.* The company released its financial performance for the quarter ended June 30, 2026, via a newspaper publication. Key metrics like revenue, profit, and margins will be closely analyzed by traders for guidance and future outlook. **Earnings announcement may trigger volatility in the counter.** 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%

*Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%*. The company posted its highest-ever quarterly revenue and earnings in Q1 FY27. EBITDA surged by **207%** while PAT jumped **394%** year-on-year. Its CDMO segment has entered full-scale commercialization, marking a key growth milestone. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen Labs reports Q1 FY26 financial results

*Morepen Labs reports Q1 FY26 financial results.* The company announced its financial performance for the quarter ended June 30, 2026. Results were submitted to the stock exchange as part of mandatory corporate disclosure. No major deviations or surprises were indicated in the filing. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings

Morepen submits first U.S. ANDA for CDMO expansion

*Morepen submits first U.S. ANDA for CDMO expansion* — Morepen Laboratories has filed its first Abbreviated New Drug Application (ANDA) in the U.S., marking a key step in its integrated CDMO strategy. The move strengthens its global footprint and could unlock future revenue streams. **First U.S. filing** enhances long-term growth prospects in the generics market. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #CDMO

Morepen completes first phase of capacity expansion ahead of schedule

*Morepen completes first phase of capacity expansion ahead of schedule.* The company has finished the initial stage of its manufacturing capacity expansion **ahead of schedule**, boosting production capabilities. This development is expected to support revenue growth and operational efficiency in the coming quarters. The expansion aligns with its long-term strategic goals in the domestic and export markets. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #CapacityExpansion

Morepen starts commercial supplies under ₹825 Cr CDMO mandate

*Morepen starts commercial supplies under ₹825 Cr CDMO mandate.* The company has commenced commercial-scale deliveries under a **₹825 crore** CDMO agreement, marking a key milestone in its contract development and manufacturing business. This order strengthens its revenue visibility and operational scale in the pharma export segment. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #CDMO

Morepen Labs shares flat after investor presentation

*Morepen Laboratories Limited held an investor presentation with no major announcements.* The stock reacted mildly, trading **flat** on the NSE. Key metrics like **Q4 revenue growth of 8% YoY** and **EBITDA margin at 15%** were reiterated. Guidance for FY25 remains unchanged. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #investor-presentation